Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

29

Revenue 2017

Soliris

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Soliris was produced by Alexion.

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Apellis jumps as pegcetacoplan tops Alexion’s Soliris in PNH trial

Shares shot up more than 50% in wake of announcement. Apellis has new data showing that its pegcetacoplan drug outperformed Alexion’s market leading Soliris in rare disease paroxysmal nocturnal haemoglobinuria ... with C5 inhibitor Soliris and

Roche’s Soliris rival satralizumab scores in phase 3 study

Roche’s Soliris rival satralizumab scores in phase 3 study Alexion also received European Commission approval for the extended use of Soliris in the same indication in August. ... However, both Roche and Alexion could face competition from biosimilars, as Amgen  recently filed a patent infringement action

US, EU regulators start review of Roche’s Soliris rival satralizumab

US, EU regulators start review of Roche’s Soliris rival satralizumab paralysis. At the moment the only approved treatment in the US is Alexion’s complement C5 inhibitor  Soliris (eculizumab), which got a green light from the FDA in June, and there ... Viela thinks inebilizumab has a dosing advantage over both Soliris

Alexion eyes Soliris combo with $930m deal to buy Achillion

Alexion eyes Soliris combo with $930m deal to buy Achillion paroxysmal nocturnal haemoglobinuria (PNH), a rare disease whose treatment is currently dominated by Alexion’s blockbuster complement C5 inhibitor  Soliris (eculizumab). ... combination with Soliris in PNH – and follow-up ACH-5228 in phase 1.

Roche presents new data in NMOSD, could challenge Alexion's Soliris

Roche presents new data in NMOSD, could challenge Alexion's Soliris Reduced risk of relapse by 55%. Roche has presented new data on satralizumab for neuromyelitis optica spectrum disorder (NMOSD),  setting it up for a potential market battle with Alexion’s Soliris. ... progression. Alexion’s Soliris received FDA

1 2 3 4 5 6 7 8 9 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Windrose Consulting Group

Windrose Consulting Group helps life science companies maximize the commercial value of their products and bring new innovations to market...

Latest intelligence

Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...
Can involving patients in design transform the clinical trial experience?
While the research space is a heavily regulated environment and there are rules that we must abide by, this doesn’t mean clinical study materials have to be ‘boring’ or the...

Infographics